 Kamada Ltd. NASDAQ TASE: KMDA, a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019, with the U.S. Securities and Exchange Commission the SEC. The annual report, including the Companys audited consolidated financial statements, can be accessed via the SECs website at as well as under the SEC Filings section on Kamadas investor relations website at The Company will deliver a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. 